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There has long been a vague supposition that the European Union (EU) has a trans-
position problem (Groenleer et al . 2010; Kaeding 2006, 2007a, b, 2008a, b, c, 2012; 
Kaeding and Versluis 2014; Klika 2015a, 2015b; Mastenbroek and Kaeding 2006, 
2007; Schmälter 2017; Steunenberg et al . 2006; Steunenberg and Kaeding 2009) . This 
chapter offers a first assessment of the timeliness of national transposition processes 
for all EU Member States and their respective national pharmacovigilance systems .
When the timeliness of national transposition processes of pharmacovigilance 
for all EU Member States is considered, this assessment shows that many countries 
have a serious transposition problem in their national pharmacovigilance systems . 
4.1 Timely Transposition of Directive 2010/84/EU across 
Member States
Fig . 4 .1 calculates the difference between the transposition deadline set in the EU 
pharmacovigilance Directive (21 .07 .2012) and the date of publication of the first 
and last national transposition instruments . The figure shows the delays in weeks 
for the 101 national implementing measures of Directive 2010/84/EU .
Whereas the average number of implementing measures needed to transpose 
the EU pharmacovigilance directive was 3 .6, 12 Member States communicated only 
one transposing instrument . However, Malta, Hungary and Lithuania needed nine, 
13 and 14 instruments, respectively .
In addition, only 16 out of the 101 (15 percent) national implementing measures 
were transposed on time . On the extreme end of the late transposition continuum 
are Finland, Spain, Poland and Slovenia; they transposed their first national imple-
menting measures more than one year after the transposition deadline had expired .
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Overall, it appears that EU transposition deficits in European pharmacovigilance 
are not a statistical illusion . Almost 85 percent of the national transposition instru-
ments are not transposed on time, and in fact are delayed up to more than two years .
Cross-country variance in transposing the EU pharmacovigilance Directive 
is significant . There is a significant difference between the laggards (Denmark 
and Slovenia) and the champions (Cyprus, Romania, Sweden, Estonia, the United 
Kingdom and Ireland) .
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Many Member States have endorsed so-called guiding principles for transposing EU 
legislation . These principles aim at policy makers and lawyers across government 
bodies and explain what is needed to correctly implement EU legislation .
When EU legislation is transposed, the aim should be to avoid going beyond 
the minimum requirements of the legal instrument being transposed . Taking such 
an approach will ensure that EU legislation does not create unnecessary legislative 
burdens . Furthermore, any gold-plating by extending the scope, adding in some 
way to the substantive requirement, not taking full advantage of any derogations, 
retaining pre-existing national standards where they are higher than those required 
by EU law, or implementing early before the date given in a directive, should be 
either avoided or eventually cleared by a reducing regulation committee . Another 
guiding implementation principle is to always use copy-out for transposition where 
it is available, except where doing so would adversely affect national interests .
In the following sections, the report analyses all national implementing mea-
sures for the six Member States (the United Kingdom, Finland, Poland, France, 
Portugal and Germany) under investigation . To assess whether they followed the 
above-mentioned guiding implementing principles, we split the analysis according 
to two aspects: processes and actors on the one hand, and quality and content on 
the other hand .
4.2.1 Correct Transposition – Processes and Actors
Table 4 .1 summarises the findings of the “processes and actors” analysis and is 
guided by the order of the following questions:
1 . What is the name, what is the type of legal instrument and who signed the 
national implementing measure (NIM)?
2 . Was there a transposition plan, and did the actors’ legal departments participate 
in this plan?
3 . Is there a reducing regulation committee or similar, were expert groups consulted 
and does the NIM provide for a ministerial review?
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4.2.2 Correct Transposition – Quality and Content
Table 4 .2 summarises the findings of the “quality and content” analysis based on 
the following questions:
1 . Has Directive 2010/84/EU been copied, or has new or existing legislation been 
used?
2 . Is the national implementing measure longer than the original legislation?
3 . Does the national implementing measure exceed the requirements of Directive 
2010/84/EU?
4 . Was the national implementing measure transposed before the transposition 
deadline on July 21st, 2012?
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All in all, however, Member States hardly pay any attention to the above-mentioned 
guiding implementing principles . The EU also has a transposition problem in terms 
of incorrect transposition . Processes, the number of actors, the quality and the 
content of national implementing measures vary greatly across the selected EU 
Member States, leading to a great deal of diversity across Europe .
This chapter demonstrated that the transposition of EU legislation into national law 
remains a challenge across the EU . Yet by now, the formal transposition of Directive 
2010/84/EU on pharmacovigilance has been completed in all Member States . In 
the following chapter, we analyse whether the transposition is also complied with 
in practice . With a focus on six EU Member States (the United Kingdom, Finland, 
Poland, France, Portugal and Germany), we depict national ADR reporting systems, 
examine which challenges remain, and identify best practices in order to improve 
existing pharmacovigilance frameworks .
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